A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
=== Chlorohydrin process of production of ethylene oxide === Although the chlorohydrin process is almost entirely superseded in the industry by the direct oxidation of ethylene, the knowledge of this method is still important for educational reasons and because it is still used in the production of propylene oxide. The process consists of three major steps: synthesis of ethylene chlorohydrin, dehydrochlorination of ethylene chlorohydrin to ethylene oxide and purification of ethylene oxide. Those steps are carried continuously. In the first column, hypochlorination of ethylene is carried out as follows:
In genetics, a strain is said to be auxotrophic if it carries a mutation that renders it unable to synthesize an essential compound. For example, a yeast mutant with an inactivated uracil synthesis pathway gene is a uracil auxotroph (e.g., if the yeast orotidine 5'-phosphate decarboxylase gene is inactivated, the resultant strain is a uracil auxotroph). Such a strain is unable to synthesize uracil and will only be able to grow if uracil can be taken up from the environment. This is the opposite of a uracil prototroph, or in this case a wild-type strain, which can still grow in the absence of uracil. Auxotrophic genetic markers are often used in molecular genetics; they were famously used in Beadle and Tatum's Nobel Prize-winning work on the one gene-one enzyme hypothesis, connecting mutations of genes to protein mutations. This then allows for biosynthetic or biochemical pathway mapping that can help determine which enzyme or enzymes are mutated and dysfunctional in the auxotrophic strains of bacteria being studied. Researchers have used strains of E. coli auxotrophic for specific amino acids to introduce non-natural amino acid analogues into proteins. For instance cells auxotrophic for the amino acid phenylalanine can be grown in media supplemented with an analogue such as para-azido phenylalanine. Many living things, including humans, are auxotrophic for large classes of compounds required for growth and must obtain these compounds through diet (see vitamin, essential nutrient, essential amino acid, essential fatty acid).
After the Boer War, the British army underwent reform focused on lessening the emphasis placed on mounted units. It was determined that the traditional role of cavalry was antiquated and improperly used on the battlefield in the Boer War, and the First World War was the proof that mounted attacks had no place in twentieth century combat. Cavalry was put to better use after the reforms in the theatres of the Middle East and World War I, and the idea of mounted infantry was useful in times when war was more mobile. An example was during the First World War during the Battle of Mons, in which the British cavalry held the Belgian town against German assault.
Chest radiography can show pneumothorax, and is indicated if there is chest discomfort or breathing difficulty Computed tomography (CT) scans and magnetic resonance imaging (MRI) may be indicated when there is severe headache or severe back pain after diving. CT is the most sensitive method to evaluate for pneumothorax. It can be used where barotrauma-related pneumothorax is suspected and chest radiograph findings are negative. Echocardiography can be used to detect the number and size of gas bubbles in the right side of the heart.
== Further reading == J. Buikstra, 1977. "Biocultural dimensions of archaeological study: a regional perspective". In:Biocultural adaptation in prehistoric America, pp. 67–84. University of Georgia Press. J. Buikstra and L. Beck, eds., 2006. "Bioarchaeology: the Contextual Study of Human Remains." Elsevier. M. Katzenberg and S. Saunders, eds., 2000. Biological anthropology of the human skeleton. Wiley. K. Killgrove, 2014. Bioarchaeology Archived 2019-06-26 at the Wayback Machine. In: Oxford Annotated Bibliographies Online. Oxford. C.S. Larsen, 1997. Bioarchaeology: interpreting behavior from the human skeleton. Cambridge University Press. Law, Matt (2019). "Beyond Extractive Practice: Bioarchaeology, Geoarchaeology and Human Palaeoecology for the People". Internet Archaeology (53). doi:10.11141/ia.53.6. S. Mays, 1998. The archaeology of human bones. Routledge. Samuel J. Redman, 2016. Bone Rooms: From Scientific Racism to Human Prehistory in Museums. Harvard University Press. M. Parker Pearson, 2001. The archaeology of death and burial. Texas A&M University Press. D. Ubelaker, 1989. Human skeletal remains: excavation, analysis, interpretation. Taraxacum. T. White, 1991. Human osteology. Academic Press.
Sources: en.wikipedia.org
== See also == List of radiographic findings associated with cutaneous conditions List of cutaneous conditions caused by mutations in keratins List of contact allergens List of histologic stains that aid in diagnosis of cutaneous conditions List of target antigens in pemphigus List of specialized glands within the human integumentary system List of cutaneous conditions associated with internal malignancy
Bactericidal permeability-increasing protein (BPI) is a 456-residue (~50kDa) protein that is part of the innate immune system, coded for in the human by the BPI gene. It belongs to the family of lipid-binding serum glycoproteins. BPI was initially identified in neutrophils, but is found in other tissues including the epithelial lining of mucous membranes. It is an endogenous antibiotic protein with potent killing activity against Gram-negative bacteria. It binds to compounds called lipopolysaccharides produced by Gram-negative bacteria. Lipolysaccharides are potent activators of the immune system; however, BPI at certain concentrations can prevent this activation. BPI was discovered by Jerrold Weiss and Peter Elsbach at New York University Medical School.
A DNA sequence is called a "sense" sequence if it is the same as that of a messenger RNA copy that is translated into protein. The sequence on the opposite strand is called the "antisense" sequence. Both sense and antisense sequences can exist on different parts of the same strand of DNA (i.e. both strands can contain both sense and antisense sequences). In both prokaryotes and eukaryotes, antisense RNA sequences are produced, but the functions of these RNAs are not entirely clear. One proposal is that antisense RNAs are involved in regulating gene expression through RNA-RNA base pairing. A few DNA sequences in prokaryotes and eukaryotes, and more in plasmids and viruses, blur the distinction between sense and antisense strands by having overlapping genes. In these cases, some DNA sequences do double duty, encoding one protein when read along one strand, and a second protein when read in the opposite direction along the other strand. In bacteria, this overlap may be involved in the regulation of gene transcription, while in viruses, overlapping genes increase the amount of information that can be encoded within the small viral genome.
==== Legal challenges ==== In Glossip v. Gross, attorneys for three Oklahoma inmates argued that midazolam could not achieve the level of unconsciousness required for surgery, meaning severe pain and suffering was likely. They argued that midazolam was cruel and unusual punishment and thus contrary to the Eighth Amendment to the United States Constitution. In June 2015, the U.S. Supreme Court ruled that they had failed to prove that midazolam was cruel and unusual when compared to known, available alternatives. The state of Nevada is also known to use midazolam in execution procedures. In July 2018, one of the manufacturers accused state officials of obtaining the medication under pretences. This incident was the first time a drug company successfully, though temporarily, halted an execution. A previous attempt in 2017, to halt an execution in the state of Arizona by another drug manufacturer was not successful.
== Description == The cap is 1.5–4 centimetres (1⁄2–1+1⁄2 in) across, dry, at first hemispheric, expanding to campanulate or convex, with an incurved margin when young. Young caps start out light brown and fade to off-white or light gray at maturity, sometimes with yellowish or brownish tones. Often developing cracks in dry weather, slightly hygrophanous, turning greenish or blue where damaged. The gills are broadly adnate to adnexed, close, starting out gray and turning black as the spores mature. The gill faces have a mottled appearance and the edges are white. The spore print is black. The stipe is 6–12 cm long by 2 to 4 mm thick, equal to slightly enlarged at the base, pruinose, colored like the cap, staining somewhat blue where bruised. The taste and odor are farinaceous.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.